Abstract
BackgroundThe standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease.MethodsBetween 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen.ResultsResponses to this regimen according to RECIST criteria were partial response (n = 9, 36%), stable disease (n = 9, 36%) and progressive disease (n = 7, 28%). During the treatment phase, frequent grade 3 or worse adverse events were hematological toxicities including white blood cell decreases (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreases (48%). No long-term adverse events were reported during the study period.ConclusionThis regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long-lasting adverse events, based on our results, severe hematological toxicity should be considered.
Highlights
The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based
Twenty-five patients with a median age of 51 years who were treated with 4′-O-tetrahydropyranyl doxorubicin (THP), IFO, and VP-16 combination therapy were included in the study
As for the best responses to chemotherapy, 9 patients were evaluated as partial response (PR), while 9 patients were classified as having stable disease (SD) and 7 had progressive disease (PD)
Summary
The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This retrospective study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease. Methods: Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. Pirarubicin (4′-O-tetrahydropyranyl doxorubicin [THP]) is an anthracycline antineoplastic antibiotic discovered by Umezawa et al that can act as a substitute for ADR [4]. The uptake velocity of THP was found to be approximately 170 times faster than that of ADR, while its cardiotoxicity was lower [5, 6]. The efficacy and safety of THP for soft tissue sarcomas has not been fully validated in clinical settings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
